Market Intelligence, Clinical Progress, and High-Purity Reagents for Squamous Cell Carcinoma and Solid Tumor Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for GPR87 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | GPR87 Extracellular Domain (ECD)-Fc Fusion Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed for native glycosylation. |
View GPR87 Products |
| Gene Delivery | GPR87 Promise-ORF / Lentivirus Premade Particles Full-length ORF for stable cell line construction. Optimized for high-expression surface display to preserve native 7-transmembrane conformation. |
View GPR87 Products |
| Benchmark Ab | Anti-GPR87 Recombinant Antibody Recombinant positive control derived from benchmark literature sequences. High specificity. |
View GPR87 Products |
| Validator | GPR87 siRNA Set For knockdown verification in target specificity assays. |
View GPR87 Products |
| Related Target A | LPAR1 Lysophosphatidic acid receptor 1; functionally linked to GPR87 signaling pathways in cell survival and migration. |
View LPAR1 Products |
| Related Target B | EGFR Epidermal growth factor receptor; highly co-expressed with GPR87 in non-small cell lung cancer (NSCLC) and a key node for combination therapy. |
View EGFR Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Conformational Integrity of 7-TM GPCR | Lentivirus Premade Particles optimized for stable host cell transduction, ensuring correct membrane insertion and folding. |
| High-Concentration Formulation Stability | Sequence-verified ECD-Fc proteins with optimized buffer formulations to prevent aggregation during biophysical screening. |
| Lack of Validated Controls | Sequence-verified clinical-grade benchmark recombinant antibodies available for assay calibration. |
| Target Specificity & Off-Target Risks | Validated siRNA pools and closely related GPCR family antigens for counter-screening protocols. |
Live GPR87 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for GPR87 therapeutics is intensifying, with major players shifting focus from traditional monoclonal antibodies to Antibody-Drug Conjugates (ADCs) and multi-specific constructs. Because GPR87 is an orphan G-protein coupled receptor overexpressed in squamous cell carcinoma of the lung (NSCLC), head and neck (HNSCC), and bladder, it serves as an ideal tumor-associated antigen (TAA). As first-generation therapies reach preclinical milestones, the next wave of R&D is targeting efficient receptor internalization and high-affinity binders that bypass the traditional limitations of targeting multi-pass membrane proteins.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Antibody-Drug Conjugates (ADC) | Oncology-focused biotechs, Academic consortia | NSCLC (Squamous), Bladder Cancer, HNSCC | Internalization Assay (Requires GPR87-expressing stable cell lines generated via high-titer Lentivirus). |
| Monoclonal Antibodies (mAbs) | Translational medicine centers | Solid Tumors, Metastatic Squamous Cancers | Epitope mapping & binding affinity (Requires high-purity GPR87 ECD-Fc fusion proteins). |
| Small Molecule / Antagonists | GPCR-targeted drug discovery platforms | Cancer Stem Cell (CSC) Eradication | Functional screening (Requires robust calcium flux or reporter assays using GPR87 Promise-ORF stable lines). |